On 15 July 2026, Fosun Pharma (Stock Codes: 600196.SH; 02196.HK) announced that its subsidiary, Fosun Pharmaceutical Industrial Development (Shenzhen) Company Limited (“Fosun Pharma (Shenzhen)”), has received the approval from the National Medical Products Administration (NMPA) for the clinical trial of FXR0906 (the “Drug”) for the treatment of Hypertriglyceridemia. Fosun Pharma (Shenzhen) intends to commence the Phase 1 clinical trial of the drug in Chinese mainland (excluding Hong Kong SAR, Macau SAR and Taiwan region) when the conditions are fulfilled.

FXR0906 is a liver-targeted small interfering RNA (siRNA) drug, which can reduce the level of APOC3 through an mRNA silencing strategy, thereby lowering serum Triglyceride level in patients with hypertriglyceridemia. FXR0906 is licensed in by Fosun Pharma, which is granted an exclusive license to research, develop, register, manufacture and commercialize the drug in Chinese mainland, Hong Kong SAR and Macau SAR.

Hypertriglyceridemia (HTG) is a common dyslipidemia. According to statistics, the prevalence of HTG (TG ≥ 2.3 mmol/L, approximately 200 mg/dL) in China is approximately 15%, and the number of patients with severe hypertriglyceridemia (sHTG, TG ≥ 5.7 mmol/L, approximately 500 mg/dL) is approximately 10 million. HTG is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis. Currently available TG-lowering drugs (such as fibrates, omega-3 fatty acids, and nicotinic acid) have limited efficacy or safety concerns, leaving a significant unmet clinical need.

The clinical study of FXR0906 in Chinese mainland will include a Phase 1 bridging study and subsequent clinical studies, designed to evaluate the drug’s safety, tolerability, pharmacokinetics, and preliminary efficacy in Chinese patients with HTG.